Floatz logo

Epirubicin

Recurrent Breast Carcinoma

UNC Lineberger Comprehensive Cancer CenterPhase 3Active
BBB
74/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
66/ 100
Competitive Position
89/ 100

Competitive context

25 Active assets in the Recurrent Breast Carcinoma cohort.

Asset / SponsorPhaseRating
TAMOXIFEN
Xijing Hospital
Phase 4BBB
Olaparib
The Netherlands Cancer Institute
Phase 4BBB
Vinorelbine
Fudan University
Phase 3BBB
CIS-DIAMMINEDICHLOROPLATINUM II
National Cancer Institute (NCI)
Phase 3BB
Temsirolimus
M.D. Anderson Cancer Center
Phase 2BB

View all 50 →

Same molecule, other indications

Epirubicin is also rated in:

Lung Non-Small Cell Squamous CarcinomaDormant
BBB
Indicative ·
72 / 100
View asset →
Advanced/Metastatic Gastroesophageal AdenocarcinomaDormant
BBB
Indicative ·
72 / 100
View asset →
Recurrent Mycosis FungoidesDormant
BB
Indicative ·
71 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →